专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06475467B1 Medicinal aerosol formulations 有权
标题翻译：药用气雾剂
公开(公告)号：US06475467B1
公开(公告)日：2002-11-05
申请号：US09744798
申请日：2001-04-20
申请人： Manfred Keller , Kurt Herzog , Rudi Müller-Walz , Holger Kraus
发明人： Manfred Keller , Kurt Herzog , Rudi Müller-Walz , Holger Kraus
IPC分类号： A61K912
CPC分类号： A61K9/008 , A61K9/124 , A61K47/22
摘要： The use of solid, pharmaceutically acceptable salts of cromoglycic acid and/or nedocromil as carriers in a therapeutically and prophylactically inefficacious amount in suspension aerosol formulations of pharmaceutical active compounds improves the dispersion properties, increases the chemical and physical stability of moisture-sensitive active compounds, makes possible a more accurate dosage, in particular even of low-dose active compounds, and as a rule permits the abandonment of surface-active agents.
摘要翻译：在治疗和预防无效量的药物活性化合物的悬浮气雾剂制剂中使用色甘酸和/或奈多罗米的固体药学上可接受的盐作为载体改善了分散性能，提高了湿敏性活性化合物的化学和物理稳定性，使得可能更准确的剂量，特别是甚至低剂量活性化合物，并且通常允许放弃表面活性剂。

2. 发明申请

US20110114092A1 Dry Powder for Inhalation 审中-公开
标题翻译：用于吸入的干粉
公开(公告)号：US20110114092A1
公开(公告)日：2011-05-19
申请号：US12946456
申请日：2010-11-15
申请人： Manfred Keller , Rudi Müller-Walz
发明人： Manfred Keller , Rudi Müller-Walz
IPC分类号： A61M15/00
CPC分类号： A61K31/56 , A61K9/0075 , A61K9/14 , A61K31/137 , A61K31/167 , A61K31/439 , A61K47/26 , A61M15/003 , A61M15/0045 , A61M15/0065 , A61M2202/064
摘要： The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. On of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
摘要翻译：本发明的目的是提高含有不可吸入粒度的药学上无效载体的吸入粉末制剂和可吸入粒径的细碎药物活性化合物的吸湿干粉配方的耐湿性，并且还提高所述制剂的储存稳定性。为此，在所述制剂中使用硬脂酸镁。关于本发明干粉的特征在于在相对极端的温度和湿度条件下也可以保持高的细颗粒剂量或细颗粒分数。

3. 发明授权

US07186401B2 Dry powder for inhalation 有权
标题翻译：用于吸入的干粉
公开(公告)号：US07186401B2
公开(公告)日：2007-03-06
申请号：US10628965
申请日：2003-07-28
申请人： Manfred Keller , Rudi Müller-Walz
发明人： Manfred Keller , Rudi Müller-Walz
IPC分类号： A61K9/12 , A61K9/14 , A61M11/00
CPC分类号： A61K9/0075 , A61K47/12
摘要： The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
摘要翻译：本发明的目的是提高含有不可吸入粒度的药学上无效载体的吸入粉末制剂和可吸入粒径的细碎药物活性化合物的吸湿干粉配方的耐湿性，并且还提高所述制剂的储存稳定性。为此，在所述制剂中使用硬脂酸镁。本发明干粉的特征之一是在相对极端的温度和湿度条件下也可以保持高的细颗粒剂量或细颗粒分数。

4. 发明授权

US06585958B1 Medicinal aerosol formulations 有权
标题翻译：药用气雾剂
公开(公告)号：US06585958B1
公开(公告)日：2003-07-01
申请号：US09744379
申请日：2001-04-13
申请人： Manfred Keller , Kurt Herzog , Rudi Müller-Walz , Holger Kraus
发明人： Manfred Keller , Kurt Herzog , Rudi Müller-Walz , Holger Kraus
IPC分类号： A61K912
CPC分类号： A61K9/008 , A61K9/124
摘要： A pressure-liquefied propellant mixture for aerosols, comprising dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the particle size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.
摘要翻译：一种用于气溶胶的压力液化推进剂混合物，其包含一氧化二氮和具有1至3个碳原子的氢氟烷烃，特别是1,1,1,2-四氟乙烷和/或1,1,1,2,3,3,3- 七氟丙烷可以改善药物活性化合物的润湿性能，由此可以克服悬浮液和溶液气溶胶存在的氢氟烷存在的配方问题，从而可以获得改进的药物气溶胶制剂。借助于一氧化二氮，还可以特别影响压力，从而影响粒度分布，并且通过从氢氟烷烃中排出氧来提高氧化敏感活性化合物的储存稳定性。如果需要，推进剂混合物可另外含有二氧化碳。

5. 发明授权

US06645466B1 Dry powder for inhalation 有权
标题翻译：用于吸入的干粉
公开(公告)号：US06645466B1
公开(公告)日：2003-11-11
申请号：US09831011
申请日：2001-08-09
申请人： Manfred Keller , Rudi Müller-Walz
发明人： Manfred Keller , Rudi Müller-Walz
IPC分类号： A61K912
CPC分类号： A61K9/0075 , A61K47/12
摘要： The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
摘要翻译：本发明的目的是提高含有不可吸入粒度的药学上无效载体的吸入粉末制剂和可吸入粒径的细碎药物活性化合物的吸湿干粉配方的耐湿性，并且还提高所述制剂的储存稳定性。为此，在所述制剂中使用硬脂酸镁。本发明干粉的特征之一是在相对极端的温度和湿度条件下也可以保持高的细颗粒剂量或细颗粒分数。

6. 发明申请

US20090232744A1 Macrolide compositions having improved taste and stability 审中-公开
标题翻译：具有改善的味道和稳定性的大环内酯组合物
公开(公告)号：US20090232744A1
公开(公告)日：2009-09-17
申请号：US12380378
申请日：2009-02-26
申请人： Manfred Keller , Evy Corbanie
发明人： Manfred Keller , Evy Corbanie
IPC分类号： A61K9/12 , A61K31/7048 , A61K31/7028
CPC分类号： A61K9/0078 , A61K31/7028 , A61K31/7048 , A61K47/12
摘要： The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.
摘要翻译：本发明提供一种用于作为气溶胶施用于呼吸道，鼻或口咽区域的水性药物组合物，其包含（i）具有差的味道和在水溶液中的化学稳定性差的大环内酯类; （ii）至少一种选自葡萄糖酸钠，天冬氨酸钠，乙酸钠，乳酸钠，琥珀酸钠，马来酸钠，葡糖酸镁，天冬氨酸镁，柠檬酸镁，乙酸镁，乳酸镁，琥珀酸镁和马来酸镁或其混合物和（iii）不同于所述盐的掩味剂; 其中（a）所述大环内酯在组合物中的浓度在约0.25重量％至约15重量％的范围内; （b）所述大环内酯：所述盐的摩尔比在约1:0.5至约1:100的范围内; （c）组合物的pH在约3至9的范围内; 和（d）组合物的重量摩尔渗透压浓度在约150mOsmol / kg至约1500mOsmol / kg的范围内。本发明还提供了一种产生气雾剂的方法，优选通过使用这种水性药物组合物的雾化器。大环内酯可以单独使用或与其他药物组合使用。该组合物适用于治疗炎症性疾病和/或呼吸道感染。它具有改善的味道和稳定性。

7. 发明申请

US20090025713A1 Nebulised Antibiotics for Inhalation Therapy 审中-公开
标题翻译：用于吸入治疗的雾化抗生素
公开(公告)号：US20090025713A1
公开(公告)日：2009-01-29
申请号：US12223735
申请日：2007-02-08
申请人： Manfred Keller , Aslihan Akkar
发明人： Manfred Keller , Aslihan Akkar
IPC分类号： A61K9/12 , A61K47/38 , A61K47/36 , A61K47/40 , A61P11/00
CPC分类号： A61K9/0078 , A61K9/0043 , A61K31/4709 , A61K31/496 , A61K31/535 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/6951 , B82Y5/00 , Y02A50/473 , Y02A50/478
摘要： The present invention provides pharmaceutical aerosols which are useful for the prevention or treatment of infectious diseases of the airways, such as the lungs, the bronchi, or the sinunasal cavities. The aerosols comprise an active agent selected from the group of quinolone antibiotics. Also disclosed are liquid and solid compositions suitable for being converted into the aerosols, and kits comprising such compositions.
摘要翻译：本发明提供了可用于预防或治疗气道如肺，支气管或鼻腔的传染病的药用气溶胶。气溶胶包含选自喹诺酮类抗生素的活性剂。还公开了适于转化成气溶胶的液体和固体组合物，以及包含这种组合物的试剂盒。

8. 发明授权

US07173712B2 Method and device for increasing the long-term operational reliability of a fiber optic interferometer 有权
标题翻译：提高光纤干涉仪长期运行可靠性的方法和装置
公开(公告)号：US07173712B2
公开(公告)日：2007-02-06
申请号：US10485579
申请日：2002-07-26
申请人： Manfred Keller
发明人： Manfred Keller
IPC分类号： G01C19/72
CPC分类号： G01C19/721
摘要： A method for increasing the long-term operational reliability of a fiber optic interferometer. Noise in a detector output signal is set to a desired value by correcting the detector light power. Detector light power is corrected by varying a light source current of a light source of the interferometer. A change in the light source power results. It is thereby possible to increase both the reliability and useful life of the interferometer.
摘要翻译：一种提高光纤干涉仪长期运行可靠性的方法。通过校正检测器光功率将检测器输出信号中的噪声设置为期望值。通过改变干涉仪的光源的光源电流来校正检测器光功率。导致光源功率的变化。从而可以提高干涉仪的可靠性和使用寿命。

9. 发明申请

US20050244339A1 Pharmaceutical aerosol composition 有权
标题翻译：药物气溶胶组成
公开(公告)号：US20050244339A1
公开(公告)日：2005-11-03
申请号：US11106999
申请日：2005-04-14
申请人： Jurgen Jauernig , Frank-Christophe Lintz , Manfred Keller , Ingo Friedrich
发明人： Jurgen Jauernig , Frank-Christophe Lintz , Manfred Keller , Ingo Friedrich
IPC分类号： A61K9/00 , A61K9/107 , A61K9/127 , A61K9/19 , A61L9/04
CPC分类号： A61K9/1075 , A61K9/0078 , A61K9/127 , A61K9/19
摘要： Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.
摘要翻译：描述了作为气溶胶施用的无菌组合物。它们含有水溶性差的活性剂，非离子表面活性剂组分和磷脂组分。所述组合物适用于口服或鼻吸入，也适用于局部或粘膜粘膜给药。它们对于有效的肺部给药难溶性皮质类固醇是特别有用的，并且可以用普通喷雾器进行雾化。

10. 发明授权

US4973227A Method of producing a vacuum 失效
标题翻译：制造真空的方法
公开(公告)号：US4973227A
公开(公告)日：1990-11-27
申请号：US367025
申请日：1989-06-16
申请人： Otto Bernauer , Clemens Halene , Manfred Keller
发明人： Otto Bernauer , Clemens Halene , Manfred Keller
IPC分类号： B01J3/00 , C01B3/00 , F04B37/02
CPC分类号： F04B37/02
摘要： A method of producing a vacuum in a volume of a hollow body which has at least one outlet opening for the gaseous atmosphere present therein, the method includes the following steps: introducing at least about 3 g/dm.sup.3 of evacuation volume of a metal hydride into the hollow body so as to take up less than about 5% of the volume 3. The metal hydride comprises a hydride forming alloy of the formulaTi(V.sub.1-a-b Fe.sub.a Al.sub.b).sub.xy Mn.sub.z,wherein1
摘要翻译：一种在具有至少一个气体气氛出口的中空体的体积中产生真空的方法，该方法包括以下步骤：将至少约3g / dm 3的金属氢化物排空体积引入空心体以便占据体积3的小于约5％。金属氢化物包括式Ti（V1-ab FeaAlb）xyMnz的氢化物形成合金，其中1 = = 0 0 z 。将金属氢化物加热到使氢化物中释放大量气态氢的温度，进行加热步骤，使中空体的加热温度不超过约500℃。用从氢化物释放的气态氢冲洗体积，从而在释放之前更换体积中存在的气体气氛; 关闭中空体的出口; 冷却空心体; 并用氢化物形成合金吸收气态氢。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式